G1 Therapeutics Inc. Common Stock
Exchange: NASDAQ
Symbol: GTHX
SEC CIK: 0001560241
Phone: 919-213-9835
700 PARK OFFICES DRIVE
SUITE 200
RESEARCH TRIANGLE PARK NC 27709
CEO: Mark Velleca
|
Price when page updated: 1.73 Date: 2023-11-30
Company Website:
www.g1therapeutics.com
|
_Description: G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.
IPO YEAR:
2017
|
Sector:
Health Care
|
Industry:
Biotechnology: Pharmaceutical Preparations
|
ADRTSO:
|
MarketCap:
89689547.00
|
Beta:
1.480786430382673
|
52 Week High:
37.07
|
52 Week Low:
9.75
|
52 Week Change:
-0.423469387755102
|
Short Interest:
|
Short Date:
|
Shares Outstanding:
42522148
|
Dividend Rate:
0
|
Dividend Yield:
N/A
|
ExDividend Date:
|
Latest EPS:
|
Latest EPS Date:
N/A
|
Float:
0
|
return on Equity:
-
|
Consensus EPS:
|
Number Of Estimates:
|
EPS Surprise Dollar:
|
Eps Surprise Percent:
|
EBITDA:
N/A
|
ttmEPS:
0
|
Revenue:
$250.397M
|
Gross Profit:
|
Cash:
|
Debt:
|
Institution Percent:
0.10%
|
Revenue Percent:
|
Revenue Per Employee:
|
Insider Percent:
51.19%
|
Return on Assets:
-
|
Return on Capital:
|
Profit Margin:
-36.50%
|
Price to Sales:
3.64
|
Price To Book:
9.82
|
Short Ratio:
0.12
|
PE Ratio:
0
|
Employees:
122
|
1Y Guesstimate
N/A:N/A:N/A
|
|
|
|
|
|
|
|
|
__The following are links to various summary and news pages for
__G1 Therapeutics Inc. Common Stock [ GTHX ].
__Note: Some Links might not have information for the company.
|
|
